T-knife Therapeutics Closes $110M Series B Financing

T-knife Therapeutics, Inc., a Berlin, Germany-based T-cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, completed a $110m Series B financing.

The round was led by Fidelity Management & Research Company, LLC., with participation from other new investors including LSP, Qatar Investment Authority (QIA), Casdin Capital, Sixty Degree Capital, and CaaS Capital, along with existing investors RA Capital Management, Versant Ventures and founding investor Andera Partners. Karin Kleinhans, PhD, Partner at LSP, joined T-knife’s board in connection with the financing. 

The company plans to use proceeds to expand its scientific team, increase manufacturing capacity and advance its pipeline of T-cell receptor (TCR) engineered T cell therapies (TCR-T).

Led by Thomas M. Soloway, Chief Executive Officer, and Alex Mayweg, Chairman of the company and Managing Director at Versant Ventures, T-knife is a next-generation T-cell receptor (TCR) company developing a pipeline of therapeutics for solid tumor patients. The company leverages its proprietary humanized T-cell receptor (HuTCR) mouse platform to produce fully human TCRs, naturally selected in-vivo for optimal affinity and specificity. T-knife is developing a pipeline of potential TCR therapeutics against targets with high unmet medical need, including cancer testis antigens, viral antigens and commonly shared neoantigens.

T-knife was founded by T-cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charité University Hospital in Berlin.